Chk1 inhibition-induced BRCAness synergizes with olaparib in p53-deficient cancer cells

References

• Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918786658.
   Web of Science ®Google Scholar
• Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16:20–33.
   PubMed Web of Science ®Google Scholar
• Patel PS, Algouneh A, Hakem R. Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand. Oncogene. 2021;40:3001–3014.
   PubMed Web of Science ®Google Scholar
• Rigakos G, Razis E. Brcaness: Finding the Achilles heel in ovarian cancer. Oncologist. 2012;17:956–962.
   PubMed Web of Science ®Google Scholar
• Noordermeer SM, van Attikum H. PARP inhibitor resistance: A tug-of-war in BRCA-mutated cells. Trends Cell Biol. 2019;29:820–834.
   PubMed Web of Science ®Google Scholar
• Zhou P, Wang J, Mishail D, et al. Recent advancements in PARP inhibitors-based targeted cancer therapy. Precision Clin Med. 2020;3:187–201.
   PubMedGoogle Scholar
• Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005;7:195–201.
   PubMed Web of Science ®Google Scholar
• Bahassi EM, Ovesen JL, Riesenberg AL, et al. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene. 2008;27:3977–3985.
   PubMed Web of Science ®Google Scholar
• Kim H, George E, Ragland R, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res. 2017;23:3097–3108.
   PubMed Web of Science ®Google Scholar
• Kim H, Xu H, George E, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726.
   PubMed Web of Science ®Google Scholar
• Burgess BT, Anderson AM, McCorkle JR, et al. Olaparib combined with an ATR or Chk1 inhibitor as a treatment strategy for Acquired Olaparib-Resistant BRCA1 mutant ovarian cells. Diagnostics. 2020;10:121.
   Web of Science ®Google Scholar
• Williams AB, Schumacher B. P53 in the DNA-Damage-Repair Process. Cold Spring Harb Perspect Med. 2016;6:a026070.
   PubMed Web of Science ®Google Scholar
• Senturk E, Manfredi JJ. P53 and cell cycle effects after DNA damage. Methods Mol Biol. 2013;962:49–61.
   PubMedGoogle Scholar
• Smits VA, Gillespie DA. DNA damage control: regulation and functions of checkpoint kinase 1. Febs J. 2015;282:3681–3692.
   PubMed Web of Science ®Google Scholar
• Parsels LA, Tanska DM, Parsels JD, et al. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle. 2016;15:730–739.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nishimura M, Onoe T, et al. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. Jpn J Clin Oncol. 2019;49:703–707.
   PubMed Web of Science ®Google Scholar
• Farago AF, Yeap BY, Stanzione M, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9:1372–1387.
   PubMed Web of Science ®Google Scholar
• Guzi TJ, Paruch K, Dwyer MP, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011;10:591–602.
   PubMed Web of Science ®Google Scholar
• Di Veroli GY, Fornari C, Wang D, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866–2868.
   PubMed Web of Science ®Google Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, et al. COSMIC: The Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2019;47:D941–D7.
   PubMed Web of Science ®Google Scholar
• Leroy B, Girard L, Hollestelle A, et al. Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum Mutat. 2014;35:756–765.
   PubMed Web of Science ®Google Scholar
• Berglind H, Pawitan Y, Kato S, et al. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther. 2008;7:699–708.
   PubMed Web of Science ®Google Scholar
• Na B, Yu X, Withers T, et al. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation. NPJ Breast Cancer. 2019;5:14.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2014;134:1013–1023.
   PubMed Web of Science ®Google Scholar
• Clementi E, Garajova Z, Markkanen E. Measuring DNA damage using the alkaline comet assay in cultured cells. Bio Protoc. 2021;11:e4119.
   PubMed Web of Science ®Google Scholar
• Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol. 2006;26:7529–7538.
   PubMed Web of Science ®Google Scholar
• Peddibhotla S, Lam MH, Gonzalez-Rimbau M, et al. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci USA. 2009;106:5159–64.29.
   PubMed Web of Science ®Google Scholar
• Willis A, Jung EJ, Wakefield T, et al. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 2004;23:2330–2338.
   PubMed Web of Science ®Google Scholar
• Chiang YT, Chien YC, Lin YH, et al. The function of the mutant p53-R175H in cancer. Cancers (Basel). 2021;13:4088.
   PubMed Web of Science ®Google Scholar
• Mayor P, Gay LM, Lele S, et al. BRCA1 reversion mutation acquired after treatment identified by liquid biopsy. Gynecol Oncol Rep. 2017;21:57–60.
   PubMed Web of Science ®Google Scholar
• Porcelli L, Quatrale AE, Mantuano P, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7:308–322.
   PubMed Web of Science ®Google Scholar
• Castedo M, Perfettini JL, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825–2837.
   PubMed Web of Science ®Google Scholar
• Bakhoum SF, Kabeche L, Murnane JP, et al. DNA-Damage response during mitosis induces whole-chromosome missegregation. Cancer Discov. 2014;4:1281–1289.
   PubMed Web of Science ®Google Scholar
• Wilhelm T, Said M, Naim V. DNA replication stress and chromosomal instability: dangerous liaisons. Genes (Basel). 2020;11:11.
   Web of Science ®Google Scholar
• Do KT, Kochupurakkal B, Kelland S, et al. Phase 1 combination study of the CHK1 inhibitor Prexasertib and the PARP inhibitor olaparib in high-grade Serous ovarian cancer and other solid tumors. Clin Cancer Res. 2021;27:4710–4716.
   PubMed Web of Science ®Google Scholar
• Mani C, Jonnalagadda S, Lingareddy J, et al. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast Cancer Res BCR. 2019;21:104.
   PubMed Web of Science ®Google Scholar